SureTrader SureTrader
Home > Boards > US Listed > Biotechs >


Add RGNX Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 10/4/2016 11:57:30 AM - Followers: 4 - Board type: Free - Posts Today: 0
We are a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Our proprietary AAV gene delivery platform (our NAV Technology Platform) consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Our mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing gene therapy products administered directly into the body, or in vivo, based on our NAV Technology Platform. We seek to accomplish our mission through a combination of our internal development efforts and the efforts of our third-party licensees (NAV Technology Licensees). Our NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, including five internally developed product candidates and 18 partnered product candidates developed by our NAV Technology Licensees.

Our most advanced internally developed candidates include programs for the treatment of two severe, rare genetic diseases: homozygous familial hypercholesterolemia (HoFH) and Mucopolysaccharidosis Type I (MPS I). We expect these programs to enter Phase I/II clinical trials in the first half of 2016. We also have a program for wet age-related macular degeneration (wet AMD) that is in the preclinical stage and for which we expect to file an Investigational New Drug application (IND) in the second half of 2016. We plan to build internal gene therapy franchises in the metabolic, neurodegenerative and retinal therapeutic areas, and develop multiple product candidates in these and other areas.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RGNX News: REGENXBIO to Present at the Jefferies Gene Editing and Gene Therapy Summit 10/04/2016 04:16:05 PM
RGNX News: REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV® Gene Therapy in Neurodegenerative Diseases 09/13/2016 07:00:00 AM
RGNX News: Current Report Filing (8-k) 09/12/2016 04:31:05 PM
RGNX News: REGENXBIO to Participate in Global Healthcare Conferences 09/07/2016 04:01:00 PM
RGNX News: Statement of Changes in Beneficial Ownership (4) 08/22/2016 04:46:50 PM
#4   RGNX bullish 14.39 stocktrademan 10/04/16 11:57:30 AM
#3   Agreed, would like to to see the stock protagonist12 06/06/16 06:52:46 PM
#2   Interesting play here for the long term. Very floWteiuQ 05/16/16 12:19:00 PM
#1   RGNX no bid support, too early still, listed VC... protagonist12 10/25/15 04:52:29 PM